StockData
Latigo Biotherapeutics, Inc. logo

Latigo Biotherapeutics, Inc. (LTGO) stock

LTGONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026
$13.76+1.16 (+9.21%)

Close on Nov 17, 2026Market cap $912.28MP/E –Yield 0.00%

Latigo Biotherapeutics cash

Cash and short-term investments held at the end of each period.

Latigo Biotherapeutics's cash was $401.24M at Sep 30, 2026. For fiscal 2025 it was $69.44M, up 287.5% from the year before.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$69.44M+287.5%
FY2024Dec 31, 2024$17.92M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026$401.24M+438.6%
Q2 FY2026Jun 30, 2026$55.00M+207.0%
Q4 FY2025Dec 31, 2025$69.44M–
Q3 FY2025Sep 30, 2025$104.64M–
Q2 FY2025Jun 30, 2025$74.50M–
Q4 FY2024Dec 31, 2024$17.92M–

More Latigo Biotherapeutics figures

See a number that looks wrong?